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Abstract (word count=250) 
Background: Older age is the most powerful risk factor for adverse coronavirus disease-19 
(COVID-19) outcomes. It is uncertain whether leucocyte telomere length (LTL), previously 
proposed as a marker of biological age, is also associated with COVID-19 outcomes. 
Methods: We associated LTL values obtained from participants recruited into UK Biobank 
(UKB) during 2006-2010 with adverse COVID-19 outcomes recorded by 30 November 2020, 
defined as a composite of any of the following: hospital admission, need for critical care, 
respiratory support, or mortality. Using information on 130 LTL-associated genetic variants, 
we conducted exploratory Mendelian randomisation (MR) analyses in UKB to evaluate 
whether observational associations might reflect cause-and-effect relationships.  
Findings: Of 6,775 participants in UKB who tested positive for infection with SARS-CoV-2 in 
the community, there were 914 (13.5%) with adverse COVID-19 outcomes. The odds ratio 
(OR) for adverse COVID-19 outcomes was 1·17 (95% CI 1·05-1·30; P=0·004) per 1-SD shorter 
usual LTL, after adjustment for age, sex and ethnicity. Similar ORs were observed in analyses 
that: adjusted for additional risk factors; disaggregated the composite outcome and reduced 
the scope for selection or collider bias. In MR analyses, the OR for adverse COVID-19 
outcomes was directionally concordant but non-significant. 
3 
 
Interpretation: Shorter LTL is associated with higher risk of adverse COVID-19 outcomes, 
independent of several major risk factors for COVID-19 including age. Further data are 
needed to determine whether this association reflects causality.   
Funding: UK Medical Research Council, Biotechnology and Biological Sciences Research 
Council and British Heart Foundation. 
Research in context 
Evidence before this study:  
We searched PubMed for articles with the terms “telomere length” and “COVID-19” to 
identify publications relating to telomere length and COVID-19 outcomes. We retained only 
research articles that used telomere length as a biomarker, identifying three articles. All of 
these studies showed a relationship between shorter telomere length and either COVID-19 
severity or outcome. However, all had measured leucocyte telomere length (TL) after SARS-
CoV-2 infection making it difficult to interpret whether shorter TL preceded infection or was 
due to higher white cell turnover in response to infection. 
Added value of this study:  
Our study is the largest study to date on the association of inter-individual variation in 
leucocyte telomere length with adverse outcomes from COVID-19 and the first to analyse 
telomere length that was measured prior to SARS-CoV-2 infection. 
Implications of all the available evidence:  
Our study suggests that independently of age, leucocyte telomere length is associated with 
greater risk of poor outcome from COVID-19, possibly through an effect on immune cell 
senescence, and that this explains some of the heterogeneity in inter-individual response to 





Older age has emerged as the most powerful risk factor for severe infection, requiring 
hospitalisation or critical care, and mortality from coronavirus disease 19 (COVID-19) caused 
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1,2  One potential 
mediator of this effect is ageing of the immune system, leading to increased levels of pro-
inflammatory senescent cells and reduced proliferative capacity of immune precursor 
cells.3,4 Telomere length (TL) is a key determinant of proliferative capacity and cellular 
lifespan, triggering senescence once a critically short TL is reached.5 TL - commonly 
measured in leucocytes (LTL) - shows a consistent negative association with age in cross 
sectional population cohorts and has previously been proposed as a marker of biological age 
for an individual. However, age only accounts for a small proportion of the substantial inter-
individual variation in LTL6 that exists at all ages, including birth.7 More recently, TL has also 
been proposed as a marker of replicative capacity and repair ability8, both of which, within 
the haematopoietic system, could potentially impair an individual’s response to SARS-CoV-2 
infection, above any effect of age.9,10 
A few small case-control studies, in which LTL was measured after SARS-CoV-2 infection at 
the time of hospital admission, have reported associations of shorter LTL with 
hospitalisation and severe outcomes.11-13 However, their interpretation is complicated by 
the possibility that LTL measurements could have been influenced by white cell turnover in 
response to infection. To our knowledge, no study to date has reported on associations of 
prior (pre-infection) LTL values and adverse COVID-19 outcomes. 
Here, we examine whether LTL measured several years prior to SARS-CoV-2 infection is 
associated with adverse COVID-19 outcomes, leveraging our recent completion of LTL 
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measurements in 474,074 participants aged 40-69 at time of recruitment into UK Biobank 




Participants: Participants in UKB have been characterised in detail using questionnaires, 
physical measurements, urinary and plasma biomarker measurements, genomic assays and 
longitudinal linkage with multiple health record systems, including Hospital Episode 
Statistics (HES) and Office for National Statistics (ONS) mortality data.16 We have described 
the associations of inter-individual variation in LTL with multiple biomedical traits and risk of 
several diseases in UKB.15 Since the onset of the COVID-19 pandemic, UKB has also linked 
participants with results from clinically indicated SARS-CoV-2 testing and COVID-19 
outcomes. By linking participants in UKB to SARS-CoV-2 testing datasets of Public Health 
England (PHE),17 we identified participants who tested positive between 16 March 2020 and 
30 November 2020; the latter date corresponds to the latest release of HES data to UKB. We 
used HES records to identify SARS-CoV-2 positive participants who were admitted to 
hospital due to COVID-19 (ICD-10 code ‘U07.1’) within 28 days after a positive SARS-CoV-2 
test. We further extracted information on need for critical care admission and respiratory 
support, due to COVID-19 (ICD-10 code ‘U07.1’), via linkage to the ICNARC (Intensive Care 
National Audit and Research Centre) database, and deaths due to COVID-19 (ICD-10 code 
‘U07.1’), from the Office for National Statistics (ONS) death registry data.   
The UK Biobank has ethical approval from the North West Centre for Research Ethics 
Committee (Application 11/NW/0382), which covers the UK. UK Biobank obtained informed 
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consent from all participants.  Full details can be found at 
https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/about-us/ethics. The 
generation and use of the data presented in this paper was approved by the UK Biobank 
access committee under UK Biobank application number 6077. 
LTL measurements: Full details of the LTL measurements in UKB are provided elsewhere.6 
Briefly, LTL was measured using an established PCR method that expresses LTL as a ratio 
(T/S ratio).6 LTL measurements were adjusted for technical variation, loge transformed and 
Z-standardised.6 In order to assess and adjust for within individual variability in LTL we 
measured LTL at two time-points (mean interval: 5·5 years) for 1,351 participants, yielding a 
regression-dilution ratio of ~0·68.  Results in this study have been corrected for within-
person variability of LTL values over time (abbreviated "usual LTL"), as described 
previously.6,15 
Outcome definitions: Our study’s primary outcome was a composite of COVID-19-related 
outcomes (ICD-10 code ‘U07.1’): hospital admission, requirement for critical care, 
respiratory support, or mortality. We defined cases as those participants in UKB who tested 
positive for SARS-CoV-2 and had the primary outcome. For our primary outcome, controls 
were those who tested positive for SARS-CoV-2 but were not hospitalised within 28 days. To 
reduce the scope for collider bias18 we included only participants with positive SARS-CoV-2 
tests done outside of hospital settings, since hospital admission itself may increase the 
likelihood of SARS-CoV-2 testing. The age, sex and ethnicity adjusted odds ratio (OR) for 
having a SARS-CoV-2 test (n=43,574) at any location, was 1·03, (95% CI 1·01-1·05; logistic 
regression P=1·0x10-4) per 1-SD shorter usual LTL. 
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We conducted several secondary analyses. First, we examined associations with each 
component of the primary composite endpoint. Second, we analysed the primary outcome 
using the rest of UKB participants as controls, as testing was unlikely to be random and the 
restriction to SARS-CoV-2 positive controls only is potentially subject to selection bias 
related to factors associated with infection.19 Third, to ensure that apparently post-COVID-
19 outcomes were not re-admissions or influenced by proximate medical events prior to 
infection, we excluded participants with any hospital admission in the previous 6 months. 
Finally, we consider the impact of inflammation and baseline disease prevalence on LTL, to 
minimise the potential confounding from these factors on any LTL-COVID-19 outcomes 
relationship. 
Statistical analysis: Univariable tests were performed using T-tests for continuous traits and 
Fishers exact or χ2 tests for categorical traits as appropriate. Analyses involved multivariable 
logistic regression, adjusting for age (at SARS-CoV-2 positive test), sex and ethnicity. Due to 
small numbers, ethnic groups other than White were combined and participants with 
missing ethnicity (n=14 cases and 46 controls) were excluded. To remove the correlation 
between LTL and age, we used the residuals of LTL adjusted for age at baseline within the 
statistical models. In specific models to estimate the impact on the association due to 
inflammation or disease prevalence we re-estimated LTL residuals adjusting for age at 
baseline and C-reactive protein or any of 123 curated diseases15 (Supplementary Table) 
respectively. ORs were further adjusted for baseline smoking status and body-mass index 
(BMI) recorded at entry into UKB. Results are described as ORs associated with the outcome 
per one standard deviation (SD) shorter LTL residual, with associated 95% confidence 
intervals (CI) and p-values.  
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In an exploratory analysis, we conducted one-sample Mendelian randomisation (MR) 
analyses in UKB20 to evaluate a causal relationship between shorter LTL and adverse COVID-
19 outcomes, using the inverse-variance weighted (IVW)21 and weighted median22 methods 
with a set of 130 genome-wide significant (P<8.31x10-9), conditionally independent, 
uncorrelated and non-pleiotropic genetic variants we recently identified as genetic 
instruments for LTL.15  We used MR-Egger regression to assess robustness to horizontal 
pleiotropy.23  
Role of the funding body: The Funders had no role in study design, data collection, data 
analyses, interpretation, or writing of this study. 
Results 
By 30 November 2020, 914 participants were identified with an adverse COVID-19 related 
outcome and 5861 participants were identified as primary controls (positive community test 
for COVID-19 but not hospitalised). Their characteristics are summarised in Table 1. On 
average, compared to controls, cases were older and more likely to be male and from a non-
White background. At time of their entry into UKB, they also had a higher BMI and more 
likely to be current smokers. (Table 1).  
LTL at entry to UKB was on average shorter in cases compared with controls (Table 1). The 
OR for the primary outcome was 1.17 (95% CI 1.05-1.30; logistic regression P=0·004) per 1-
SD shorter usual LTL, after adjustment for age, sex and ethnicity (Table 2). The OR only 
slightly attenuated after further adjustment for smoking status and BMI (OR=1·15, 1·03-
1·28), and after adjustment for the presence of any of 123 diseases recorded at baseline 
(OR=1·14, 1·02-1·26), while adjusting for CRP slightly increased the estimated effect size 
(OR=1·19, 1·06-1·33). As expected, older age, male sex and non-White ethnicity were each 
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associated with higher risk of adverse COVID-19 outcomes independently of usual LTL (Table 
2).  
Sub-components of our study’s primary composite outcome were not mutually exclusive, as 
46 cases contributed to all four sub-components (Figure 1). Shorter usual LTL was 
significantly associated with higher risk of each sub-component (Table 2). ORs were broadly 
similar to the main findings in analyses that replaced the SARS-CoV-2-positive control group 
with all UKB participants as controls or that excluded any participant with a hospital 
admission in the six months prior to testing positive for SARS-CoV-2 (Table 2).  
In MR analyses, the IVW odds ratio was 1·30 (0·85-2·00; MR-IVW P=0·224) per 1-SD shorter 
genetically-determined LTL, a non-significant result directionally concordant with the 
observational finding (Table 2). Results were similar using the weighted median method 
(Table 2) and there was no evidence of horizontal pleiotropy (MR-Egger intercept P=0·591).  
 
Discussion 
In a study of 6,775 participants with a positive test for SARS-CoV-2 (nested within the 
500,000-participant UKB), we have shown that individuals with shorter LTL assessed several 
years prior to SARS-CoV-2 infection had higher risk of adverse COVID-19 outcomes, even 
after adjustment for several established risk factors for COVID-19 including age. This finding 
suggests that shorter LTL is likely to be independently associated with COVID-19 
hospitalisation and severity. The results of analysis of LTL-associated genetic variants and 
COVID-19 were directionally concordant with our observational findings but non-significant. 
Our results, therefore, encourage further investigation of the potential causal relevance of 
TL to adverse COVID-19 outcomes.  
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The validity of our results is supported by several observations. First, our study found 
associations between older age, male sex, and non-White ethnicity that have previously 
been linked with adverse COVID-19 outcomes in the UK.2 Each of these factors was 
associated much more strongly with COVID-19 outcomes than was shorter LTL. Second, we 
found significant associations of shorter LTL with each sub-component of our study’s 
primary composite outcome. Third, our main findings persisted after adjustment for 
multiple risk factors. Fourth, our overall result was robust to sensitivity analyses designed to 
minimise the scope for potential biases. For example, collider bias can lead to false 
associations between a risk factor and an outcome,18 as highlighted by studies related to 
understanding of COVID-19 disease risk and severity.19 Indeed, we found evidence for 
potential colliders in our own analysis, observing a small but significant association between 
shorter LTL and higher likelihood of SARS-CoV-2 testing. Hence, we only included 
participants with a positive SARS-CoV-2 test outside the hospital setting, as hospitalisation 
itself may increase the likelihood of testing. Finally, considering the potential impact of 
inflammageing on the observed result we further adjusted for C-reactive protein and found 
no meaningful changes in the association.  
The biological mechanisms through which shorter LTL might increase risk of adverse 
outcomes from SARS-CoV-2 infection remain to be clarified. Our finding that the association 
was not substantially attenuated when we adjusted for the association of LTL with multiple 
diseases at baseline, suggest that, if this association is causal, it is probably not simply a 
reflection of co-morbidity due to the impact of shorter LTL on risk of these diseases. A 
potential mechanism relates to the impact of telomere length dynamics on aging of the 
immune system24 and the potential role of senescence in severe SARS-CoV-2 infection.3,4,25 
While we have measured TL in leucocytes we believe these results likely reflects TL within T-
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cells in this scenario, although further studies would be required to confirm this. When 
challenged with infection, individuals with shorter LTL prior to infection would potentially 
have less proliferative capacity within the T-cell population required for an efficient 
response to SARS-CoV2, coupled with reduced lymphopoiesis following infection.9,26 
Individuals with shorter LTL may also potentially already harbour a higher proportion of 
senescent T-cells, reducing the number of functional cells that are able to respond to 
infection.25 Additionally, senescent cells are known to adopt a pro-inflammatory phenotype, 
secreting high levels of cytokines, which can further drive inflammation in COVID-19 
patients.25 Our results are also in concordance with previous studies showing that shorter 
LTL increases the risk of adverse outcome in other infections. 27,28 
Our study has several limitations. UKB is not representative of the general UK population; 
only 6% of those invited to participate did so.29 The age distribution within UK Biobank 
includes participants aged 40-70 at baseline, who will be about 10-15 years older now, 
limiting the ability to assess association in individuals in other age groups. We were unable 
to fully assess ethnicity due to small numbers, though over time this limitation can be 
resolved with increased case numbers. Risk factor levels and mortality rates are lower than 
in the general population, although risk factor associations with mortality for a range of 
diseases are similar.30 Hence, further studies are warranted in other populations. Our one-
sample Mendelian randomisation analysis in UKB had limited power to reliably estimate 
causal effects as fewer than one thousand participants had been hospitalised after a 
positive SARS-CoV-2 test and our genetic instrument of 130 variants, while using the most 
up to date information on LTL-associated variants, accounts for only ~4% of inter-individual 
variation in LTL.15 While there are data from large genetic studies of COVID-1931, they could 
not be used in our analysis because the outcome definitions differed substantially from 
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those we used, and because of their inclusion of within hospital testing that is potentially a 
collider with LTL and COVID-19 outcomes. Larger sample sizes with comparable disease 
phenotypes should, therefore, enable more precise evaluation of a potential causal 
association between shorter LTL and adverse COVID-19 outcomes.  
In conclusion, in the largest study to date, we provide evidence that shorter LTL is 
associated with higher risk of adverse COVID-19 outcomes, independent of several major 
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Table 1. Characteristics of participants by case status. 
Trait Cases N=914 Controls N=5861 P-value 
Age at COVID-19 test 70 (8.00) 64 (8.00) 1.85E-95 
BMI 29.61 (5.39) 27.97 (4.86) 1.55E-20 
Sex Male 573 (62.69) 2675 (45.64) 
8.20E-22 Female 341 (37.31) 3186 (54.36) 
Ethnicity Asian 33 (3.61) 217 (3.70) 
0.006 
Black 5 (0.55) 38 (0.65) 
Chinese 3 (0.33) 9 (0.15) 
Mixed 36 (3.94) 117 (2.00) 
Other 8 (0.88) 78 (1.33) 
White 829 (90.70) 5402 (92.17) 
Smoking Never 358 (39.43) 3236 (55.38) 
1.27E-18 
Ex-smoker 408 (44.93) 2001 (34.25) 
Current 142 (15.64) 606 (10.37) 
LTL (age adjusted) -0.14 (0.97) -0.03 (1.00)  0.002 
Data shown are mean (SD) for continuous traits or n (%) for categorical traits. LTL, smoking 
status, BMI, sex and ethnicity are from baseline information. LTL is log-transformed and Z-
standardised. P-values were obtained via t-tests for continuous traits, Ethnicity was 




Table 2. Results of the main and secondary/sensitivity analyses.  
 
 N cases N controls Odds Ratio (95%CI) P-value 
Composite outcome 
LTL (age-adjusted) (per 1 SD shorter) 
914 5861 
1·17 (1·05 , 1·30) 0·004 
Age at COVID-19 test (per 5 yrs older) 1·58 (1·51 , 1·65) <0·001 
Sex (male vs female) 1·88 (1·62 , 2·19) <0·001 
Ethnicity (non-White vs White) 1·80 (1·39 , 2·34) <0·001 
Separate components as outcome* 
Hospitalisation 672 
5861 
1·17 (1·03 , 1·32) 0·013 
Critical care support 383 1·31 (1·12 , 1·53) <0·001 
Respiratory support 279 1·36 (1·13 , 1·64) <0·001 
Death 157 1·36 (1·07 , 1·72) 0·013 
Population controls 
LTL (age-adjusted) (per 1 SD shorter) 914 465,946 1·19 (1·08 , 1·31) <0·001 
Excluding participants with recent hospitalisation 
LTL (age-adjusted) (per 1 SD shorter) 732 5861 1·15 (1·02 , 1·30) 0·019 
Mendelian Randomisation 
MR IVW 914 5861 1.30 (0.85 , 2.00) 0·224 
MR-median   1.25 (0.62 , 2.50) 0·537 
 
The main analysis is based on our composite outcome and the full multivariable model 
estimates are shown for each risk factor. *For each component of the composite outcome 
analysed separately, the results shown for these are labelled by outcome component but 
represent the LTL (age-adjusted) estimate (per 1 SD shorter). For each analysis, the numbers 
of cases and controls are given alongside the odds ratio, 95% confidence interval and P-
value (from logistic regression models or MR). MR IVW: Mendelian randomisation inverse-






Figure 1. Venn diagram showing the distribution of the individual components of the 





Where N is the frequency and: Hospitalised, due to COVID-19; Critical care admission,  due 
to COVID-19; Respiratory Support needed, while in critical care due to COVID-19; Death due 
to COVID-19.  
Disease category Disease outcome Sex specific
 COVID cohort 
prevalent cases (N) 
 UK Biobank 
prevalent cases (N) UK Biobank self-reported
UK Biobank ICD10 
codes
UK Biobank ICD9 
codes UK Biobank OPCS4 codes
UK Biobank 
operation codes
Cancer Bladder 19 1,315 Bladder cancer (20001:1035) C67 188
Cancer Brain 6 284 Brain cancer / primary malignant brain tumour 
(20001:1032)




Cancer Breast F 91 10,486 Female only. Breast cancer (20001:1002) C50, D05 174
Cancer Cervical F 75 4,819 Cervical cancer (20001:1041) or cin/pre-cancer 
cells cervix (20001:1072)
C53 180
Cancer Colorectal 30 2,773
Large bowel / colorectal cancer, colon cancer / 
sigmoid cancer, rectal cancer or anal cancer 
(20001: [1020, 1022, 1023, 1021])
C18-C21 153, 154.0-154.1
Cancer Head and neck 10 985
Larynx/throat cancer (20001:1006), parotid 
gland cancer (20001:1015), other salivary gland 
cancer (20001:1016), lip cancer (20001:1010), 
tongue cancer (20001:1011), gum cancer 
(20001:1012), mouth cancer (20001:1077), 
tonsil cancer (20001:1078), 
oropharynx/oropharyngeal cancer (20001:1079), 
nasal cavity cancer (20001:1007), sinus cancer 
(20001:1009), cancer of lip/mouth/pharynx/oral 
cavity (20001:1004)
C32, C30, C00–C14 161, 140–149
Cancer Kidney 9 679 Kidney/renal cell cancer (20001:1034) C64, C65, C66 189
Cancer Leukemia 9 705
Leukaemia (20001:1048), acute myeloid 
leukaemia (20001:1074), chronic lymphocytic 
(20001:1055) or chronic myeloid (20001:1056)
C91-C95 204-208
Cancer Liver 0 195 Liver / hepatocellular cancer (20001:1024) C22 155
Cancer Lung 8 414
Lung cancer, small cell or non-small cell lung 
cancer (20001:[1001,1027,1028], Age lung 
cancer (not mesothelioma) diagnosed by doctor 
(22160:age)
C33
Cancer Lymphoma 16 1,778
Lymphoma (20001:1047), Hodgkins 
(20001:1052) or non-Hodgkins lymphoma 
(20001:1053), multiple myeloma (20001:1050)
C81-C88,C90 200-203




Cancer Oesophageal 3 237 Oesophageal cancer (20001:1017) C15 150
Cancer Ovary F 10 904 Ovarian cancer (20001:1039) or fallopian tube 
cancer (20001:1087)
C56 183
Cancer Pancreas 0 112 Pancreas cancer (20001:1026) C25 157
Cancer Prostate M 42 3,375 Male only. Prostate cancer (20001:1044) C61 185
Cancer Sarcoma 4 323 Sarcoma / fibrosarcoma (20001:1068) C49 171
Cancer Small intestine 1 253 Small intestine / small bowel cancer 
(20001:1019)
C17 152
Cancer Stomach 1 242 Stomach cancer (20001:1018) C16 151
Cancer Testicular M 8 796 Testicular cancer (20001:1045) C62 186
Cancer Thyroid 6 484 Thyroid cancer (20001:1065) C73 193
Cancer Uterus F 10 1,287 Uterine/endometrial cancer (20001:1040) C54-C55 179, 182
Cardiovascular Aortic valve stenosis 6 657 Aortic stenosis (20002:1490) I35.0 424.1
Cardiovascular Atrial fibrillation 106 7,237 Atrial fibrillation (20002:1471) or atrial flutter 
(20002:1483)
I48 427.3
Cardiovascular Coronary artery disease 264 19,232
Heart attack / myocardial infarction 
(20002:1075), heart attack diagnosed by a 
doctor (6150:1), age heart attack diagnosed 
(3894:age), date of myocardic infarction 
(42000:date), date of STEMI (42002:date), date 
of NSTEMI (42004:date)










Cardiovascular Heart failure 34 2,249 Heart failure / pulmonary odema (20002:1076) I50,I11.0,I13.0,I13.2 428
Cardiovascular Hypertension 811 56,615
Blood pressure medications (6177:2, 6153:2), 
vascular / heart problems diagnosed by doctor - 
high blood pressure (6150:4), high systolic 
blood pressure (BP), automated reading 
(4080:>140), high systolic BP, manual reading 
(93:>140), high diastolic BP, automated 
reading (4079:>90), high diastolic BP, manual 
reading (94:>90), age high blood pressure 
diagnosed (2966:age)
I10-I13, I15 401-405
Cardiovascular Peripheral vascular disease 34 2,507
Peripheral vascular disease (PVD) (20002:1067) 
or leg claudication / intermittent claudication 
(20002:1087)
I73.9, I74 443.9, 444
Cardiovascular Raynaud's 21 1,699 Raynaud's phenomenon / disease (20002:1561) I73.0 443
Cardiovascular Stroke 128 8,167
Stroke (20002:1081), subarachnoid 
haemorrhage (20002:1086), ischaemic stroke 
(20002:1583), vascular/heart problems 
diagnosed by doctor - stroke (6150:3), age 
stroke diagnosed (4056:age), date of stroke 
(42006:date), age of ischaemic stroke 
(42008:date), age of intracerebral haemmorage 






Cardiovascular Varicose 560 35,645
Varicose veins (20002:1494), varicose ulcer 
(20002:1593) I83, I84 454
Varicose vein surgery 
(20004:1479)
Cardiovascular Venous thromboembolism 220 13,018
Venous thromboembolic disease (20002:1068), 
pulmonary embolism (20002:1093) or deep 
venous thrombosis (DVT) (20002:1094)
I26, I80, I81, I82, 
I74, I63.6, I67.6
415.1, 451-453
Digestive Abdominal hernia 6 530 Abdominal hernia (20002:1511) K45-K46 T98
Digestive Appendicitis 121 7,709 Appendicitis (20002:1502) K35-K37 540-543 H01, H02, H03
Digestive Coeliac disease 25 2,163 Malabsorption / coeliac disease (20002:1456), 
coeliac disease or gluten sensitivity (21068:1)
K90.0 579




5690, 211.3, 211.4, 
2095
H481
Digestive Diverticulitis 190 13,227 Diverticular disease / diverticulitis 
(20002:1458)
K57, K38.2 562 H12.1
Digestive Gallstone 128 9,431 Cholelithiasis / gall stones (20002:1183) K80 574 Gallstones removed 
(20004:1528)
Digestive Gastro-oesophageal reflux disease 474 29,406 Gastro-oesophageal reflux or gastric reflux 
(20002:1138)
K21 530.11, 530.81 G24-G25
Digestive Haemorrhoids 119 9,573 Haemorroids / piles (20002:1505) K64 455
Haemorroidectomy / 
piles surgery / 
banding of piles 
(20004:1483)
Digestive Hiatus hernia 292 20,487 Hiatus hernia (20002:1474) K44.0, K44.1, K44.9 552.3, 553.3, 551.3 G23
Digestive Inflammatory bowel disease 72 5,116
Inflammatory bowel disease (20002:1461), 
Crohn's disease (20002:1462) or ulcerative 
colitis (20002:1463)
K50-K51 555-556
Digestive Inguinal hernia 163 12,279 Inguinal hernia (20002:1513) K40 5500, 5501, 5509 T19,T20,T21
Digestive Irritable bowel syndrome 239 13,619 Irritable bowel syndrome (20002:1154) K58 564.1
Digestive Liver cirrhosis 34 1,723
Liver failure / cirrhosis (20002:1158), primary 
biliary cirrhosis (20002:1136), alcoholic liver 
disease or alcoholic cirrhosis (20002:1604)
K70, K74 571
Digestive Oesophagitis 21 1,411 Oesophagitis / barretts oesophagus 
(20002:1139)
K20, K22.7 530.10, 530.85





Digestive Peptic ulcer 151 9,604
Peptic ulcer (20002:1400), duodenal ulcer 
(20002:1457) or gastric / stomach ulcers 
(20002:1142)
K25-K28 531-533 G35,G52
Peptic ulcer surgery 
(20004:1566), 
Gastric ulcer surgery 
(20004:1567)
Digestive Peritonitis 30 1,982 Peritonitis (20002:1190)
K65, K67, N733, 
N734, N735, A1831, 
A5485, A7481
567, 56889, 0140, 
03283, 0952, 09886, 
6145, 6147
Digestive Umbilical hernia 47 2,734 Umbilical hernia (20002:1512) K42 5511, 5521, 5531 T24,T97











Endocrine Type-2 diabetes 338 22,461
Diabetes type II (20002:1223), generic diabetes 











Endocrine Hyperthyroidism 55 4,327 Hyperthyroidism / thyrotoxicosis (20002:1225) E05 242.9
Endocrine Hypothyroidism 339 23,840 Hypothyroidism / myxoedema (20002:1226) E03.9 244.9
Genitourinary Benign breast lump F 41 3,404 Female only. Breast lump (20002:1666) D24, N608, N609 217, 6108, 6109
Genitourinary Benign prostatic hyperplasia M 121 10,443
Male-only. Enlarged prostate (20002:1396) or 
benign prostatic hypertrophy (BPH) 
(20002:1516)
N40 600
Genitourinary Breast cyst F 73 7,039 Female only. Breast cysts (20002:1367) N60.0-N60.4 610.0-610.4
Breast cyst / abscess 
removal 
(20004:1513)
Genitourinary Chronic kidney disease 11 1,308
Renal / kidney failure (20002:1192) requiring 
dialysis (20002:1193) or not requiring dialysis 
(20002:1194)
N18 585
L74.6, M01.1, M01.2, M01.3, M01.4, M01.5, M01.8, M01.9, M02.6, M02.7, M08.4, 
M17.2, M17.4, M17.8, M17.9, X40.1, X40.2, X40.3, X40.5, X40.6, X41.1, X41.2, X42.1
Genitourinary Endometriosis F 117 6,825 Female-only. Endometriosis (20002:1402) N80 617
Genitourinary Female infertility F 7 1,119 Female-only. Female infertility (20002:1403) N97.0 628






M06.1, M09, M09.1, M09.2, M09.3, M09.4, M09.8, M09.9, M14, M14.1, M14.8, M14.9, 
M16.4, M23.1, M26.1, M26.2, M26.3, M27.1, M27.2, M27.3, M28, M28.1, M28.2, M28.3, 
M28.4, M28.5, M28.8, M28.9, M31, M31.1, M31.8, M31.9, M39.1, M44.2, M75.4, M86.1
Percutaneous / open 
kidney stone surgery 
/ lithotripsy 
(20004:1197)
Genitourinary Ovarian cyst F 201 11,902
Female-only. Ovarian cyst or cysts 
(20002:1349), polycystic ovaries / polycystic 
ovarian syndrome (20002:1350)
N83.0-N83.2, E282, 
D27 620.0-620.2, 2564 Q474, Q493
Ovarian cyst removal 
/ surgery 
(20004:1506)













Immune Allergy/hypersensitivity 264 15,721




Z9102, T886, Z88, 
Z91103-Z9109, 
K0855
995.0, V1381, 9956, 
997, 99527, 52566, 
9953, V150
Immune Atopic dermatitis 200 13,074 L20 691.8
Immune Immunodeficiency 15 544




07953, 2790, 2791, 
2792, 2793, 79571, 
042, V08
Immune Systemic lupus erythematosus 11 701 Systemic lupus erythematosis (20002:1381) M32, H0112, L93 710.0, 37334, 6954
Immune Polymyalgia rheumatica 15 1,050 Polymyalgia rheumatica (20002:1377) M31.5, M35.3 725
Immune Psoriasis 107 6,191 Psoriasis (20002:1453) L40 696
Immune Sarcoidosis 8 1,077 Sarcoidosis (20002:1371) D86 135
Immune Sjogren's syndrome 4 559 Sjogren's syndrome / sicca syndrome 
(20002:1382)
M35.0 710.2
Infections Helicobacter pylori 21 1,364 Helicobacter pylori (20002:1442) B9681 41.86
Infections Hepatitis 39 2,833
Self-reported history of hepatitis, infective and 
non-infective hepatitis, hepatitis ABCDE 
(20002:1155, 20002:1156, 20002:1157, 
20002:1578, 20002:1579, 20002:1580, 
20002:1581, 20002:1582)
B15-B19, K73
070, 5714, 5731, 
5732, 5733
Infections Malaria 7 795 Malaria (20002:1441) B50-B54 84
Infections Measles 86 7,129 Measles / morbillivirus (20002:1568) B05 55
Infections Meningitis 43 2,032 Meningitis (20002:1247) G00-G02,A39 320–321
Infections Mononucleosis 18 1,197 Infectious mononucleosis / glandular fever / 
epstein barr virus (1567)
B27 75
Infections Mumps 37 4,460 Mumps / epidemic parotitis (20002:1569),  
ICD10:  ICD9-CM: 
B26 72
Infections Pertussis 12 1,489 Whooping cough / pertussis (20002:1572) A37 33
Infections Rheumatic fever 21 1,464 Rheumatic fever (20002:1479) I00-I02 390, 391, 392
Infections Rubella 23 2,564 Rubella / german measles (20002:1570) B06 56
Infections Scarlatina 12 1,179 Scarlet fever / scarlatina (20002:1677) A38 34.1
Infections Tuberculosis 45 2,874 Tuberculosis (20002:1440), Age tuberculosis 
diagnosed by doctor (22157:age)
A15-A19 010-018
Infections Varicella 124 9,747 Chickenpox (20002:1571), varicella 
(20002:1674) or shingles (20002:1573)
B01-B02 052, 053
Musculoskeletal Gout 128 7,108 Gout (20002:1466) M10 274
Musculoskeletal Intervertebral disc disease 202 12,940 Prolapsed disc / slipped disc (20002:1312) or 
disc degeneration (20002:1533)
M50-M51 722
V29, V29.1, V29.2, V29.3, V29.4, V29.5, V29.6, V29.8, V29.9, V30, V30.1, V30.2, V30.3, 
V30.4, V30.5, V30.6, V30.8, V30.9, V31, V31.1, V31.2, V31.3, V31.4, V31.8, V31.9, V32, 
V32.1, V32.2, V32.3, V32.4, V32.8, V32.9, V33, V33.1, V33.2, V33.3, V33.4, V33.5, 
V33.6, V33.7, V33.8, V33.9, V34, V34.1, V34.2, V34.3, V34.4, V34.5, V34.6, V34.7, 
V34.8, V34.9, V35, V35.1, V35.2, V35.8, V35.9, V36, V36.1, V36.2, V36.3, V36.8, V36.9, 
V51, V51.1, V51.8, V51.9, V52, V52.1, V52.2, V52.3, V52.4, V52.5, V52.8, V52.9, V58, 
V58.1, V58.2, V58.3, V58.8, V58.9, V59, V59.1, V59.2, V59.3, V59.8, V59.9, V60, V60.1, 
V60.2, V60.3, V60.8, V60.9, V61, V61.1, V61.2, V61.3, V61.8, V61.9, V62, V62.1, V62.2, 
V62.3, V62.8, V62.9, V63, V63.1, V63.2, V63.3, V63.8, V63.9
Musculoskeletal Osteoarthritis/spodylopathy 389 22,082 Osteoarthritis (20002:1465)
M150, M151, M152, 
M1599, M16, M160, 
M161, M169, M17, 
M170, M171, M179, 
M18, M180, M181, 





























71538, 71539, 7158, 
7159, 715, 7150, 




71518, 71519, 7210, 
7212, 7213, 7219a
Musculoskeletal Osteoporosis 106 9,225 Osteoporosis (20002:1309) M80-M82 733
Musculoskeletal Rheumatoid arthritis 83 6,078 Rheumatoid arthritis (20002:1464) M05-M06 714
Musculoskeletal Sciatica 87 6,063 Sciatica (20002:1476) M54.3-M54.4 724.3
Musculoskeletal Spondylitis 94 5,740









Dementia (Alzheimer's) 0 17 F00, G30 331
Neurological/psychia
tric
Anorexia 7 687 Anorexia / bulimia / other eating disorder 
(20002:1470)





Anxiety 130 8,340 Anxiety / panic attacks (20002:1287) F40-F41 300
Neurological/psychia
tric






Depression (20002:1286), Probable Recurrent 
major depression (severe) (20126:3), Probable 
Recurrent major depression (moderate) 
(20126:4), Single Probable major depression 





Epilepsy 77 4,550 Epilepsy (20002:1264) G40-G41 345
Neurological/psychia
tric Mania / bipolar disorder 27 1,568
Mania / bipolar disorder / manic depression 
(20002:1291), Bipolar I Disorder (20126:1), 






Migraine 229 15,739 Migraine (20002:1265) G43 346
Neurological/psychia
tric
Multiple sclerosis 14 1,764 Multiple sclerosis (20002:1261) G35 340
Neurological/psychia
tric




Parkinson's disease 15 841 Parkinson's disease (20002:1262) G20-G21, F02.3 332
Neurological/psychia
tric




tric Vertigo 92 4,590
Self-reported history of meniere's disease, 
vertigo, or labyrinthitis (20002:1421, 
20002:1500, 20002:1499)
H81, R42 438.85, 780.4
Respiratory Asthma 960 58,504
Asthma (20002:1111), age asthma diagnosed 




Chronic obstructive pulmonary 
disease 151 9,859
COPD (20002:1112) or emphysema / chronic 
bronchitis (20002:1113), age COPD diagnosed 
(22150:age)
J40-J44 490-492, 495-496
Respiratory Hayfever 460 30,053 Hayfever or allergic rhinitis (20002:1387) J30,J31 477
Respiratory Nasal polyps 69 4,726 Nasal polyps (20002:1417) J33 471
Nasal polyp surgery / 
nasal polypectomy 
(20004:1559)
Respiratory Otitis media 16 1,316 Otitis media (not self-reported) H65-H66 381-382
Respiratory Pleurisy 30 2,057 Pleurisy (20002:1125) R09.1 511.0, 511.1
Respiratory Pneumonia 203 12,968 Pneumonia (20002:1398) J10-J18, J20-J22 466, 480-487
Respiratory Pneumothorax 12 1,169 Spontaneous pneumothorax / recurrent 
pneumothorax (20002:1126)
J93.0, J93.1, J9381 512.0, 512.81, 
512.82
Respiratory Sinusitis 95 5,379 Chronic sinusitis (20002:1416) J01, J32 461, 473
Respiratory Sleep apnoea 59 3,253 Sleep apnoea (20002:1123) G47.3 327.2, 780.57




Sensory Cataract 202 16,247




C71.1, C71.2, C71.3, C71.8, C71.9, C72.1, C72.2, C72.3, C72.8, C72.9, C73.1, C73.2, 
C73.3, C73.4, C73.8, C73.9, C74.1, C74.2, C74.3, C74.8, C74.9, C75.1, C75.2, C75.3, 
C75.4, C75.8, C75.9, C77.1, C77.2, C77.6, C77.8, C77.9
Cataract extraction / 
lens implant 
(20004:1435)
Sensory Diabetic eye disease 52 2,474
Diabetic eye disease (20002:1276), Age when 
diabetes-related eye disease diagnosed 
(5901:age)
H36, E10.3, E11.3, 
E12.3, E13.3, E14.3 250.5, 3620, 36641
Sensory Glaucoma 76 6,257
Glaucoma (20002:1277), Age glaucoma 
diagnosed (4689:age) H40-H42 365
C60.1, C60.2, C60.3, C60.4, C60.5, C60.6, C60.8, C60.9, C61.1, C61.2, C61.3, C61.4, 
C61.5, C61.8, C61.9, C62.1, C62.2, C62.3, C62.4, C62.8, C62.9
Glaucoma surgery / 
trabeculectomy 
(20004:1436)
Sensory Meniere's disease 25 1,433 Meniere's disease (20002:1421) H81.0 386
Sensory Retinal detachment 41 2,802 Retinal detachment (20002:1281) H330, H332, H333, 
H334
3610, 3612, 3618 C81,C81.1,C81.2,C81.8,C81.9
Sensory Tinnitus 20 1,564 Tinnitus (20002:1597) H93.1 388.3
Supplementary Table: Disease outcome definitions and case numbers in UK Biobank. Defining 123 diseases in UK Biobank using self-reported, ICD9, ICD10, OPSC4 and operation codes to 
correctly identify cases. We defined the baseline date as the date of sample collection that telomere length was measured in. Prevalent cases are those that are identified to have occurred 
prior to baseline. Data for the COVID sample and the entire UK Biobank cohort are shown.
